Consistent with the FDA approval, the National Comprehensive Cancer Network’s 2022 Clinical Practice Guidelines for Head and Neck Cancers recommend pembrolizumab monotherapy for tumors that express PD-L1 with CPS ≥1 (category 1) and in combination with platinum and 5-FU chemotherapy (category 1) as the preferred 1L treatment option for R/M HNSCC (14). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.